Cost of treating to a modified european atherosclerosis society LDL-C target. Comparison of atorvastatin with fluvastatin, pravastatin and simvastatin

Clinical Drug Investigation

Volumn 17, Issue 3, 1999, Pages 185-193

  Smith, D G ^a   Leslie, S J ^b   Szucs, T D ^c   McBride, S ^d   Campbell, L M ^e   Calvo, C ^f   Lecerf, J M ^g   Fellin, R ^h  

^a UNIVERSITY OF MICHIGAN   (United States)

^b Parke Davis Pharmaceutical Research   (Germany)

^c UNIVERSITY OF MILAN   (Italy)

^d PFIZER INC   (United States)

^e Southbank Surgery   (United Kingdom)

^f HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^g LILLE UNIVERSITY HOSPITAL   (France)

^h UNIVERSITY OF FERRARA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; COLESTYRAMINE; FLUINDOSTATIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; SIMVASTATIN;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST CONTROL; DRUG COST; DRUG TOLERABILITY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0033044791     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-199917030-00003     Document Type: Article

References (44)

1. Herbert PR, Gaziano JM, Chan KS, et al. Cholesterol lowering with stahn drugs, risk of stroke, and total mortality: an overview of randomized trials. JAMA 1997; 278: 313-21
2. Brown WV. Landmark trials in lipid reduction. Value Health 1998; 1: 110-4
3. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9
4. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia. N Engl J Med 1995; 333: 1301-7
5. Jönsson B, Johannesson M, Kjekshus J, et al. Cost-effectiveness of cholesterol-lowering: results from the Simvastatin Survival Study. Eur Heart J 1996; 17: 1001-7
6. Caro J, Klittich W, McGuire A, et al. The West of Scotland Coronary Prevention Study: economic benefit analysis of primary prevention with pravastatin. BMJ 1997; 315: 1577-82
7. Morris S, McGuire A, Caro J, et al. Strategies for the management of hypercholesterolaemia: a systematic review of the cost-effectiveness literature. J Health Serv Res Policy 1997; 2: 231-50
8. Huse DM, Russell MW, Miller JD, et al. Cost-effectiveness of statins. Am J Cardiol 1998; 82: 1357-63
9. Glick H, Heyse JF, Thompson D, et al. A model for evaluating the cost-effectiveness of cholesterol reducing treatment. Int J Technol Assess Health Care 1992; 8: 719-34
10. Cullen P, Assmann G. Treatment goals for low-density lipoprotein cholesterol in the secondary prevention of coronary heart disease: absolute levels or extent of lowering? Am J Cardiol 1997; 80: 1287-94
11. Pearson TA, Laurora IM. Treatment success in patient subgroups in the Lipid Treatment Assesment Project (L-TAP) [abstract 361]. Circulation 1997: 96 (8)
12. Ramsay LE, Haq IU, Jackson PR, et al. Targeting lipid-lowering drug therapy for primary prevention of coronary disease: an updated Sheffield table. Lancet 1996; 348: 387-8
13. Bennett W, McNee W, Melcalfe S. In New Zealand, subsidy of statins is limited to particular groups of patients [letter]. BMJ 1997; 315: 1616
14. Schwartz JS, Brown WV, Hlatky M, et al. Cardiovascular disease and lipoproteins: available evidence and remaining questions: reactor panel and open forum. Value Health 1998; 1: 125-30
15. Pyörälä K, De Backer G, Graham I, et al. on behalf of the Task Force. Prevention of coronary heart disease in clinical practice: recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Eur Heart J 1994; 15: 1300-31
16. Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). JAMA 1993; 269: 3015-23
17. Haq UR, Jackson PR, Yeo WW, et al. Sheffield risk and treatment table for cholesterol lowering for primary prevention of coronary heart disease. Lancet 1995; 346: 1467-71
18. Tunstall-Pedoe H, Woodward M, Tavendale R, et al. Comparison of the prediction by 27 different factors of coronary heart disease and death in men and women of the Scottish heart health study: cohort study. BMJ 1997; 315: 722-6
19. Muldoon MF, Criqui MH. The emerging role of statins in the prevention of coronary heart disease: statins are effective but we need better ways of assessing risk. BMJ 1997; 315: 1554-5
20. Hjalte K, Lindgren B, Persson U. Cost-effectiveness of simvastatin versus cholestyramine: results for Sweden. Pharmacoeconomics 1992; 1: 213-6
21. O'Connor PJ, Rush WA, Trence DL. Relative effectiveness of macin and lovastatin for treatment of dyslipidemias in a health maintenance organization. J Fam Pract 1997; 44: 462-7
22. Dart A, Jerums G, Nicholson G, et al. A multicenter, doubleblind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia. Am J Cardiol 1997; 80: 39-44
23. Davidson M, McKenney J, Stein E, et al. Comparison of oneyear efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia: atorvastatin study group I. Am J Cardiol 1997; 79: 1475-81
24. Bertolini S, Bon GB, Campbell LM, et al. Efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia. Atherosclerosis 1997; 130: 191-7
25. Sasaki S, Sawada S, Nakata T, et al. Crossover trial of samvastatin versus pravastatin in patients with primary hypercholesterolemia. J Cardiovasc Pharmacol 1997; 30: 142-7
26. Rindone JP, Arriola G, Hiller D, et al. Changes in serum lipids when fluvastatin is substituted for lovastatin in the same doses. Am J Cardiol 1997; 80: 348-9
27. Davidson MH, Nawrocki JW, Weiss SR, et al. Effectiveness of atorvastatin for reducing low-density lipoprotein cholesterol to National Cholesterol Education Program treatment goals. Am J Cardiol 1997; 80: 347-8
28. Heudebert GR, Van Ruiswyk J, Hiatt J, et al. Combination therapy for hypercholesterolaemia: the trade-off between cost and simplicity. Arch Intern Med 1993; 153: 1828-37
29. Koren MJ, Smith DG, Hunninghake DB, et al. The cost of reaching National Cholesterol Education Program (NCEP) goals in hypercholesterolaemic patients: a comparison of atorvastatin, simvastatin, lovastatin and fluvastatin. Pharmacoeconomics 1998; 14: 59-70
30. Jones P, Kafonek S, Laurora I, et al. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin and fluvastatin in patients with hypercholesterolemia (The CURVES study). Am J Cardiol 1997; 81: 582-7
31. Perreault S, Hamilton VH, Lavoie F. A head-to-head comparison of the cost-effectiveness of HMG-CoA reductase inhibitors and fibrates in different types of hyperlipidemia. Cardiovasc Drug Ther 1997; 10: 787-94
32. Nawrocki JW, Weiss SR, Davidson MH, et al. Reduction of LDL-cholesterol by 25% to 60% in patients with primary hypercholesterolaemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Vase Biol 1995; 15: 678-82
33. Black D, Davidson M, Koren M, et al. Cost effectiveness of treatment to National Cholesterol Education Panel (NCEP) targets with HMG-CoA reductase inhibitors: trial design. Pharmacoeconomics 1997; 12: 278-85
34. Prevention of coronary heart disease - scientific background and new clinical guidelines. Recommendations of the European Atherosclerosis Society prepared by the International Task Force for Prevention of Coronary Heart Disease. Nutr Metabol Cardiovasc Dis 1992; 2: 113-56
35. MIMS, March 1997
36. Murray CJL, Lopez AD. Global burden of disease. New York, NY: World Health Organization, 1996
37. Mutdoon MF, Criqui MH. The emerging role of statins in the prevention of coronary heart disease. BMJ 1997; 315: 1554-5
38. Mehl B, Santell JP. Projecting future drug expenditures - 1998. Am J Health Syst Pharm 1998; 55: 127-36
39. Oster G. The economics of hypercholesterolemia and lipid-lowering therapy: a brief historical tour. Value Health 1998; 1: 159-66
40. Field K, Thorogood M, Silagy C, et al. Strategies for reducing coronary risk factors in primary care: which is the most costeffective? BMJ 1995; 310: 1109-12
41. Koopmanschap MA, Rutten FF. The impact of indirect costs on outcomes of health care programs. Health Econ 1994; 3: 385-93
42. Andrade SE, Walker AM, Goulieb LK. Discontinuation of antihyperlipidemic drugs: do rates reported in clinical trials reflect rates in primary care settings? N Engl J Med 1995; 332: 1125-31
43. Smith DG. Adherence to lipid-lowering guidelines in managed care settings. Drug Benefit Trends 1998; 10: 29-34
44. Schectman G, Hiatt J. Drug therapy for hypercholesterolemia in patients with cardiovascular disease: factors limiting achievement of lipid goals. Am J Med 1996; 100: 197-204